tldrdailynews.com logo

KRAS combo data prompts Revolution Medicines toward Phase 3

1 min read
Source: Endpoints News
KRAS combo data prompts Revolution Medicines toward Phase 3
Photo: Endpoints News
TL;DR

Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.

Topics:businessbiotech#biotech#daraxonrasib#esmo#kras-g12d#kras-inhibitor#revolution-medicines
Share this article
  1. Revolution Medicines shares promising data around KRAS drug combination  Endpoints News
  2. Experimental cancer drug brings time and hope for patients  WSAW
  3. Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026  Yahoo Finance
  4. Practice-Changing Data in GI Oncology  Medscape
  5. Why 1000 Doctors Gave This Cancer Drug A Standing Ovation?  Oncodaily

Want the full story? Read the original reporting

Read on Endpoints News